236 related articles for article (PubMed ID: 35603567)
1. Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study.
Zhong S; Zhang Z; Guo Z; Yang W; Dou G; Lv X; Wang X; Ge J; Wu B; Pan X; Wang H; Mou Y
Bioengineered; 2022 May; 13(5):12003-12020. PubMed ID: 35603567
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the inhibitory behavior of XFE and mitoxantrone molecules in interaction with AKT1 protein: a molecular dynamics simulation study.
Amiran MR; Taghdir M; Abasi Joozdani F
J Mol Model; 2023 Apr; 29(5):153. PubMed ID: 37086344
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
4. Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.
Mahajan P; Wadhwa B; Barik MR; Malik F; Nargotra A
Mol Divers; 2020 Feb; 24(1):45-60. PubMed ID: 30798436
[TBL] [Abstract][Full Text] [Related]
5.
Sharif Siam MK; Sarker A; Sayeem MMS
J Biomol Struct Dyn; 2021 Oct; 39(17):6467-6479. PubMed ID: 32746771
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC.
Yadav RP; Chatterjee S; Chatterjee A; Pal DK; Ghosh S; Acharya K; Das M
J Recept Signal Transduct Res; 2022 Dec; 42(6):599-607. PubMed ID: 36125981
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation.
Zhu J; Li K; Xu L; Cai Y; Chen Y; Zhao X; Li H; Huang G; Jin J
J Adv Res; 2022 Feb; 36():1-13. PubMed ID: 35127160
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase 4 promotes tumorigenesis and glucose metabolism in glioma by activating AKT1 signaling.
Wang B; Zhang X; Li ZS; Wei C; Yu RZ; Du XZ; He YJ; Ren Y; Zhen YW; Han L
Cancer Lett; 2024 Mar; 585():216665. PubMed ID: 38290657
[TBL] [Abstract][Full Text] [Related]
9. 3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway.
Zhang L; Zheng Y; Zeng L; Zhang F; Che D; Cao Z; Huang C; Xian L; Zhang X; Zhang H; Guo Z
Life Sci; 2021 Nov; 285():119995. PubMed ID: 34592228
[TBL] [Abstract][Full Text] [Related]
10. Identification of allosteric inhibitor against AKT1 through structure-based virtual screening.
Karunakaran K; Muniyan R
Mol Divers; 2023 Dec; 27(6):2803-2822. PubMed ID: 36522517
[TBL] [Abstract][Full Text] [Related]
11. Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities.
Li T; Wang G
Int J Mol Sci; 2014 Oct; 15(10):18856-91. PubMed ID: 25334061
[TBL] [Abstract][Full Text] [Related]
12. Virtual Screening of Natural Compounds as Potential PI
Dotolo S; Cervellera C; Russo M; Russo GL; Facchiano A
Molecules; 2021 Jan; 26(2):. PubMed ID: 33477701
[TBL] [Abstract][Full Text] [Related]
13. New in-capillary electrophoretic kinase assays to evaluate inhibitors of the PI3k/Akt/mTOR signaling pathway.
Nehmé R; Nehmé H; Saurat T; de-Tauzia ML; Buron F; Lafite P; Verrelle P; Chautard E; Morin P; Routier S; Bénédetti H
Anal Bioanal Chem; 2014 Jun; 406(15):3743-54. PubMed ID: 24817345
[TBL] [Abstract][Full Text] [Related]
14. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
[TBL] [Abstract][Full Text] [Related]
15. Computational study on new natural compound inhibitors of Traf2 and Nck-interacting kinase (TNIK).
Ma L; Li R; Yao Z; Wang B; Liu Y; Liu C; Wang H; Chen S; Sun D
Aging (Albany NY); 2022 Oct; 14(20):8394-8410. PubMed ID: 36287174
[TBL] [Abstract][Full Text] [Related]
16. Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian Cancer.
Ajjarapu SM; Tiwari A; Taj G; Singh DB; Singh S; Kumar S
BMC Pharmacol Toxicol; 2021 Nov; 22(1):68. PubMed ID: 34727985
[TBL] [Abstract][Full Text] [Related]
17. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
18. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.
Zhang C; Yang N; Yang CH; Ding HS; Luo C; Zhang Y; Wu MJ; Zhang XW; Shen X; Jiang HL; Meng LH; Ding J
PLoS One; 2009; 4(3):e4881. PubMed ID: 19293927
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening.
Yilmaz OG; Olmez EO; Ulgen KO
Comput Biol Chem; 2014 Feb; 48():1-13. PubMed ID: 24291487
[TBL] [Abstract][Full Text] [Related]
20. Akt Serine/Threonine Kinase 1 Regulates de Novo Fatty Acid Synthesis through the Mammalian Target of Rapamycin/Sterol Regulatory Element Binding Protein 1 Axis in Dairy Goat Mammary Epithelial Cells.
Zhang T; Huang J; Yi Y; Zhang X; Loor JJ; Cao Y; Shi H; Luo J
J Agric Food Chem; 2018 Feb; 66(5):1197-1205. PubMed ID: 29323924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
